by ASTCT Talks and Oncology On the Go
In a special cobranded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks, Rahul Banerjee, MD, FACP, a...
Preclinical evidence warrants further testing of P2X7 blockades as a preventative therapy against graft-versus-host disease (GVHD), a complication of allogeneic hematopoietic stem cell...
IFNγ blockade curtails the incidence of high-grade toxicities associated with chimeric antigen receptor (CAR) T-cell therapy, researchers report. Observations from a murine model of toxicities...
Findings from a real-world study affirm belumosudil as a promising option for patients with chronic graft-versus-host disease and inadequate response to at least two prior lines of therapy. The...
Contrary to conventional practice recommending against upfront hematopoietic cell transplantation (HCT) for severe aplastic anemia (SSA), except in the case of young recipients with matched...
by ASTCT Talks
In this episode of ASTCT Talks, supported by an educational grant from Sanofi US, host Dr. Corey Cutler, MD, from Dana-Farber Cancer Institute, sits down with Dr. Sanjeet Singh Dadwal, MD, chief...